Search research articles
Contact Us
Filters
Showing results (41-50 of 52) with videos related to
Page
of 6
Sort By:
The Journal of Headache and Pain
|
August 6, 2023
Exploring sensory sensitivity, cortical excitability, and habituation in episodic migraine, as a function of age and disease severity, using the pattern-reversal task
Angela Marti-Marca, Adrià Vilà-Balló, Xim Cerda-Company, et al.
Headache
|
March 26, 2025
Patient satisfaction with calcitonin gene-related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study
Alba López-Bravo, Ane Mínguez-Olaondo, Candela Nieves-Castellanos, et al.
Cephalalgia : an International Journal of Headache
|
November 4, 2020
Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution
Edoardo Caronna, Alejandro Ballvé, Arnau Llauradó, et al.
The Journal of Headache and Pain
|
July 18, 2021
MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
Robert Belvís, Pablo Irimia, Patricia Pozo-Rosich, et al.
Pain and Therapy
|
September 26, 2021
Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients
Raffaele Ornello, Fayyaz Ahmed, Andrea Negro, et al.
Frontiers in Neurology
|
June 28, 2024
Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study
María Pilar Navarro-Pérez, Vicente González-Quintanilla, Albert Muñoz-Vendrell, et al.
International Journal of Environmental Research and Public Health
|
September 9, 2022
Excellent Response to OnabotulinumtoxinA: Different Definitions, Different Predictors
Raffaele Ornello, Carlo Baraldi, Fayyaz Ahmed, et al.
Pain and Therapy
|
March 29, 2021
Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study
Raffaele Ornello, Fayyaz Ahmed, Andrea Negro, et al.
The Journal of Headache and Pain
|
June 2, 2023
Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients
Albert Muñoz-Vendrell, Sergio Campoy, Edoardo Caronna, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
May 22, 2024
Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world
Edoardo Caronna, Victor José Gallardo, Gabriella Egeo, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 52) with videos related to
Sort By:
Page
of 6
The Journal of Headache and Pain
|
August 6, 2023
Exploring sensory sensitivity, cortical excitability, and habituation in episodic migraine, as a function of age and disease severity, using the pattern-reversal task
Angela Marti-Marca, Adrià Vilà-Balló, Xim Cerda-Company, et al.
Headache
|
March 26, 2025
Patient satisfaction with calcitonin gene-related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study
Alba López-Bravo, Ane Mínguez-Olaondo, Candela Nieves-Castellanos, et al.
Cephalalgia : an International Journal of Headache
|
November 4, 2020
Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution
Edoardo Caronna, Alejandro Ballvé, Arnau Llauradó, et al.
The Journal of Headache and Pain
|
July 18, 2021
MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
Robert Belvís, Pablo Irimia, Patricia Pozo-Rosich, et al.
Pain and Therapy
|
September 26, 2021
Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients
Raffaele Ornello, Fayyaz Ahmed, Andrea Negro, et al.
Frontiers in Neurology
|
June 28, 2024
Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study
María Pilar Navarro-Pérez, Vicente González-Quintanilla, Albert Muñoz-Vendrell, et al.
International Journal of Environmental Research and Public Health
|
September 9, 2022
Excellent Response to OnabotulinumtoxinA: Different Definitions, Different Predictors
Raffaele Ornello, Carlo Baraldi, Fayyaz Ahmed, et al.
Pain and Therapy
|
March 29, 2021
Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study
Raffaele Ornello, Fayyaz Ahmed, Andrea Negro, et al.
The Journal of Headache and Pain
|
June 2, 2023
Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients
Albert Muñoz-Vendrell, Sergio Campoy, Edoardo Caronna, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
May 22, 2024
Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world
Edoardo Caronna, Victor José Gallardo, Gabriella Egeo, et al.
Page
of 6